Back to Journals » Cancer Management and Research » Volume 12

LINC00963 Confers Oncogenic Properties in Glioma by Regulating the miR-506/BCAT1 Axis

Authors Ye F, Xu R, Ge Y, Zheng Y, Liu X, Deng P, Xu X

Received 16 January 2020

Accepted for publication 16 March 2020

Published 27 March 2020 Volume 2020:12 Pages 2339—2351

DOI https://doi.org/10.2147/CMAR.S246332

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Chien-Feng Li


Feng Ye, Ronghua Xu, Yuanhong Ge, Yi Zheng, Xiaowei Liu, Pingfu Deng, Xuejun Xu

Department of Neurosurgery, The Second People’s Hospital of Chengdu, Chengdu, Sichuan 610021, People’s Republic of China

Correspondence: Xuejun Xu
Department of Neurosurgery, The Second People’s Hospital of Chengdu, 10 Qingyun South Street, Chengdu, Sichuan 610021, People’s Republic of China
Email xuxejun@163.com

Background: Glioma is a prevalent disease of the central nervous system with a high incidence and mortality rate. Many long noncoding RNAs (lncRNAs) have been determined to be critical regulators of glioma oncogenesis. However, the function and mechanism of LINC00963 in glioma have not been fully elucidated.
Methods: The expression level of RNA was determined by qRT-PCR, and the protein level was determined by Western blot analysis. A luciferase activity assay was conducted to verify the interaction between miRNA and lncRNA or the target gene. The proliferation, cell cycle distribution, invasion, and migration were evaluated by MTT, EdU, flow cytometry, wound-healing and Transwell invasion assays, respectively. In vivo tumor growth was evaluated in a xenograft nude mouse model.
Results: We found that LINC00963 was upregulated in glioma cells and tissues and associated with the poor prognosis of patients with glioma. Ectopic expression of LINC00963 promoted cell proliferation, cell cycle progression, migration, and invasion in vitro and tumorigenesis in vivo. Mechanistically, the results of luciferase activity and RNA pulldown assays validated that LINC00963 could act as a molecular sponge of miR-506. Reciprocal repression was found between LINC00963 and miR-506. In addition, BCAT1 was identified as a target of miR-506, and both the mRNA and protein levels of BCAT1 were reduced by miR-506. In tumor tissues, the expression of BCAT1 was negatively and positively correlated with miR-506 and LINC00963 expression, respectively. The reintroduction of BCAT1 in glioma cells abolished the tumor suppressive function of miR-506 by promoting cell viability and motility. The upregulated LINC00963 and BCAT1 were associated with the aggressive phenotypes of tumors.
Conclusion: Our data revealed that LINC00963 confers oncogenic function in the progression of glioma and that the LINC00963/miR-506/BCAT1 axis may be a novel mechanism and therapeutic strategy for this disease.

Keywords: LINC00963, miR-506, BCAT1, glioma, ceRNA, invasion


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]